Bittensor's Subnet 68 launches AI-driven drug discovery challenges to revolutionize pharma

Bittensor’s Subnet 68 has launched three live competitions to speed up drug discovery. The projects cover molecule screening, nanobody design, and search optimisation. Over 11 million molecules have already been evaluated across nine disease targets in the first challenge alone. The first competition focuses on small molecule screening for nine active disease targets. So far, more than 11 million compounds have been assessed as part of this effort.

The second challenge centres on nanobody design, specifically targeting PD-L1. Around 4,200 nanobody structures are currently under evaluation. The third competition aims to refine search methods for chemical space. A total of 63 unique algorithms are competing to improve efficiency in this area. Metanova Labs is leveraging decentralised miners on Subnet 68 to accelerate drug discovery at a reduced cost. The OpenTensor Foundation has publicly acknowledged the subnet as proof of Bittensor’s wider potential. Yuma Consensus, a stake-weighted validator agreement, drives Bittensor’s incentive framework. It rewards high-quality research outputs across various fields, including drug discovery and AI language models. This structure helps remove bottlenecks in traditional pharmaceutical pipelines, speeding up development.

The three competitions demonstrate how decentralised networks can transform drug research. By using Bittensor’s framework, participants are cutting costs and increasing efficiency. The results could reshape how pharmaceutical development operates in the future.